BMC Cancer 2008, 8:36 http://www.biomedcentral.com/1471-2407/8/36 25. Wulfing P, Diallo R, Muller C, Wulfing C, Poremba C, Heinecke A, Rody A, Greb RR, Bocker W, Kiesel L: Analysis of cyclooxygen- ase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 2003, 129:375-382. 26. Papadaki I, Mylona E, Giannopoulou I, Markaki S, Keramopoulos A, Nakopoulou L: PPARgamma expression in breast cancer: clin- ical value and correlation with ERbeta. Histopathology 2005, 46:37-42. 27. Fritah A, Saucier C, Mester J, Redeuilh G, Sabbah M: p21WAF1/ CIP1 selectively controls the transcriptional activity of estro- gen receptor alpha. Mol Cell Biol 2005, 25:2419-2430. 28. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F, Weisz A: 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex acti- vation and p105Rb phosphorylation during mitogenic stimu- lation of G(1)-arrested human breast cancer cells. Oncogene 1996, 12:2315-2324. 29. Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ: Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 2006, 94:253-258. 30. Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A: COX-2 over- expression increases motility and invasion of breast cancer cells. Int J Oncol 2005, 26:1393-1399. 31. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ: COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004, 90:423-429. 32. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joen- suu H, Isola J: Prognostic significance of elevated cyclooxygen- ase-2 expression in breast cancer. Cancer Res 2002, 62:632-635. 33. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC: Cyclo-oxygenase 2 expression is associated with angiogen- esis and lymph node metastasis in human breast cancer. J Clin Pathol 2002, 55:429-434. 34. O'Connor JK, Avent J, Lee RJ, Fischbach J, Gaffney DK: Cyclooxyge- nase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radio- therapy. Int J Radiat Oncol Biol Phys 2004, 58:1034-1040. 35. Dannenberg AJ, Howe LR: The role of COX-2 in breast and cer- vical cancer. Prog Exp Tumor Res 2003, 37:90-106. 36. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Sub- baramaiah K, Dannenberg AJ: Cyclooxygenase-2 is over- expressed in human cervical cancer. Clin Cancer Res 2001, 7:429-434. 37. Arun B, Goss P: The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 2004, 31:22-29. 38. Brueggemeier RW, Diaz-Cruz ES: Relationship between aro- matase and cyclooxygenases in breast cancer: potential for new therapeutic approaches. Minerva Endocrinol 2006, 31:13-26. 39. Solin LJ, Fourquet A, Vicini FA, Haffty B, Taylor M, McCormick B, McNeese M, Pierce LJ, Landmann C, Olivotto IA, Borger J, Kim J, de la RA, Schultz DJ: Mammographically detected ductal carci- noma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status. Int J Radiat Oncol Biol Phys 2001, 50:991-1002. 40. Cutuli B, Cohen-Solal-le NC, de LB, Mignotte H, Fichet V, Fay R, Servent V, Giard S, Charra-Brunaud C, Lemanski C, Auvray H, Jac- quot S, Charpentier JC: Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. Int J Radiat Oncol Biol Phys 2002, 53:868-879. 41. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ: Cyclooxyge- nase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002, 277:18649-18657. 42. Schmitz KJ, Callies R, Wohlschlager J, Kimmig R, Otterbach F, Bohr J, Lee HS, Takeda A, Schmid KW, Baba HA: Overexpression of cyclooxygenase-2 is an independent predictor of unfavoura- ble outcome in node-negative breast cancer but is not asso- ciated with protein kinase B (Akt) and mitogen-activated protein kinases (ERK1/2, p38) activation or with Her-2/neu signalling pathways. J Clin Pathol 2006. 43. Grommes C, Landreth GE, Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor gamma ago- nists. Lancet Oncol 2004, 5:419-429. 44. Koeffler HP: Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 2003, 9:1-9. 45. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998, 1:465-470. 46. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP: Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refrac- tory breast cancer: a phase II study. Breast Cancer Res Treat 2003, 79:391-397. 47. Spiegelman BM: PPAR-gamma: adipogenic regulator and thia- zolidinedione receptor. Diabetes 1998, 47:507-514. 48. Suzuki T, Hayashi S, Miki Y, Nakamura Y, Moriya T, Sugawara A, Ishida T, Ohuchi N, Sasano H: Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions. Endocr Relat Cancer 2006, 13:233-250. 49. Pignatelli M, Cortes-Canteli M, Lai C, Santos A, Perez-Castillo A: The peroxisome proliferator-activated receptor gamma is an inhibitor of ErbBs activity in human breast cancer cells. J Cell Sci 2001, 114:4117-4126. 50. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S: Induction of solid tumor differenti- ation by the peroxisome proliferator-activated receptor- gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 1999, 96:3951-3956. 51. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: Ligands for peroxi- some proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998, 95:8806-8811. 52. Badawi AF, Badr MZ: Expression of cyclooxygenase-2 and per- oxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis. Int J Cancer 2003, 103:84-90. 53. Jiang WG, Redfern A, Bryce RP, Mansel RE: Peroxisome prolifera- tor activated receptor-gamma (PPAR-gamma) mediates the action of gamma linolenic acid in breast cancer cells. Prostaglandins Leukot Essent Fatty Acids 2000, 62:119-127. 54. Yoshimura N, Sano H, Okamoto M, Akioka K, Ushigome H, Kadotani Y, Yoshimura R, Nobori S, Higuchi A, Ohmori Y, Nakamura K: Expression of cyclooxygenase-1 and -2 in human breast can- cer. Surg Today 2003, 33:805-811. 55. Watanabe O, Shimizu T, Imamura H, Kinoshita J, Utada Y, Okabe T, Kimura K, Hirano A, Yoshimatsu K, Aiba M, Ogawa K: Expression of cyclooxygenase-2 in malignant and benign breast tumors. Anticancer Res 2003, 23:3215-3221. 56. Schrey MP, Patel KV: Prostaglandin E2 production and metab- olism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Cancer 1995, 72:1412-1419. 57. Vargas C, Kestin L, Go N, Krauss D, Chen P, Goldstein N, Martinez A, Vicini FA: Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy. Int J Radiat Oncol Biol Phys 2005, 63:1514-1521. 58. Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R: The prognostic signifi- cance of multiple morphologic features and biologic mark- ers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer 2004, 100:2317-2327. 59. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC: Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007, 38:197-204. 60. Ringberg A, Anagnostaki L, Anderson H, Idvall I, Ferno M: Cell bio- logical factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and his- topathological characteristics. Eur J Cancer 2001, 37:1514-1522. 61. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R, Dimitrov N, Kavanah M: Lumpectomy and radiation therapy for the treat- ment of intraductal breast cancer: findings from National Page 10 of 11 (page number not for citation purposes)